Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
暂无分享,去创建一个
P. Serruys | S. Silber | S. Windecker | C. Di Mario | B. Xu | P. Widimsky | Shuzheng Lu | Weimin Wang | Bo Xu
[1] A. Yeung,et al. Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[2] P. Serruys,et al. Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. , 2014, The Journal of invasive cardiology.
[3] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[4] H. Suryapranata,et al. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. , 2014, JACC. Cardiovascular interventions.
[5] S. Silber,et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. , 2014, European heart journal.
[6] Shaoliang Chen,et al. One-year outcomes from an all-comers chinese population of patients implanted with the resolute zotarolimus-eluting stent. , 2014, The American journal of cardiology.
[7] P. Serruys,et al. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. , 2014, JACC. Cardiovascular interventions.
[8] P. Serruys,et al. Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program. , 2013, International journal of cardiology.
[9] T. Henry,et al. Clinical outcomes in real‐world patients with acute myocardial infarction receiving XIENCE V® everolimus‐eluting stents , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[10] M. Kern,et al. Realigning Venus and Mars: The sexual equality of STEMI patients , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] G. Stone,et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. , 2013, Journal of the American College of Cardiology.
[12] B. Xu,et al. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial. , 2013, JACC. Cardiovascular interventions.
[13] C. Terkelsen,et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). , 2013, JACC. Cardiovascular interventions.
[14] Sunilkumar,et al. Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segment–Elevation Myocardial Infarction , 2013 .
[15] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[16] Michael J Pencina,et al. Repeat Revascularization After Contemporary Percutaneous Coronary Intervention: An Evaluation of Staged, Target Lesion, and Other Unplanned Revascularization Procedures During the First Year , 2012, Circulation. Cardiovascular interventions.
[17] M. Krucoff,et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. , 2012, JACC. Cardiovascular interventions.
[18] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.
[19] Dick M. Goedhart,et al. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[20] E. Wall,et al. OUTCOME OF SECOND-GENERATION EVEROLIMUS- AND ZOTAROLIMUS-ELUTING STENTS IN ST-ELEVATION MYOCARDIAL INFARCTION , 2012 .
[21] F. Neumann,et al. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[22] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[23] J. Tijssen,et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele , 2011, JACC. Cardiovascular interventions.
[24] F. Alfonso,et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). , 2010, JACC. Cardiovascular interventions.
[25] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[26] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[27] P. Serruys,et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[28] P. Serruys,et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. , 2009, JACC. Cardiovascular interventions.
[29] V. Novack,et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. , 2009, JACC. Cardiovascular interventions.
[30] Aloke V. Finn,et al. Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.
[31] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[32] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.